BLCM Bellicum Pharmaceuticals Inc.

1.88
-0.26  -12%
Previous Close 2.14
Open 2.25
Price To Book 94
Market Cap 93,858,472
Shares 49,924,719
Volume 3,115,095
Short Ratio
Av. Daily Volume 1,336,307
Stock charts supplied by TradingView

NewsSee all news

  1. Bellicum Presents New Translational Data for BPX-601 at ASCO GI Cancers Symposium

    HOUSTON, Jan. 24, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today presented new Phase 1 translational

  2. Bellicum Pharmaceuticals Enters into Asset Purchase and Master Services Agreements with MD Anderson

    Houston manufacturing facility and portions of Bellicum's Technical Operations and Quality staff to be acquired by MD Anderson Current and future GoCAR™ product candidates to be manufactured by MD Anderson HOUSTON,

  3. Bellicum Pharmaceuticals to Present New Translational Data for BPX-601 at ASCO 2020 Gastrointestinal Cancers Symposium

    HOUSTON, Jan. 16, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that an abstract on new Phase 1

  4. Bellicum Pharmaceuticals Licenses Its CaspaCIDe® Safety Switch to MD Anderson

    HOUSTON, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that The University of Texas MD

  5. Bellicum Pharmaceuticals Presents Encouraging Preclinical Data for GoCAR-NK Cell Program at Society for Immunotherapy of Cancer Annual Meeting

    iMC activation enhances innate NK cell cytotoxicity against tumor cell lines in vitro MC activity enhances the efficacy of CAR-NK cells against hematological and solid tumor models MC signaling synergizes with

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 pediatric top-line data met primary endpoint of event free survival - July 8, 2019.
BPX-501 Rivo-cel
Adjunct T-cell therapy administered after allogeneic HSCT - (hematopoietic stem cell transplantation) - cancer
Phase 1 Cohort 5C data due 2H 2020.
BPX-601
Pancreatic cancer
Phase 2/3 trial on hold pending partnership.
Rivo-cel -THRIVE
Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS)

Latest News

  1. Bellicum Presents New Translational Data for BPX-601 at ASCO GI Cancers Symposium

    HOUSTON, Jan. 24, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today presented new Phase 1 translational

  2. Bellicum Pharmaceuticals Enters into Asset Purchase and Master Services Agreements with MD Anderson

    Houston manufacturing facility and portions of Bellicum's Technical Operations and Quality staff to be acquired by MD Anderson Current and future GoCAR™ product candidates to be manufactured by MD Anderson HOUSTON,

  3. Bellicum Pharmaceuticals to Present New Translational Data for BPX-601 at ASCO 2020 Gastrointestinal Cancers Symposium

    HOUSTON, Jan. 16, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that an abstract on new Phase 1

  4. Bellicum Pharmaceuticals Licenses Its CaspaCIDe® Safety Switch to MD Anderson

    HOUSTON, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that The University of Texas MD

  5. Bellicum Pharmaceuticals Presents Encouraging Preclinical Data for GoCAR-NK Cell Program at Society for Immunotherapy of Cancer Annual Meeting

    iMC activation enhances innate NK cell cytotoxicity against tumor cell lines in vitro MC activity enhances the efficacy of CAR-NK cells against hematological and solid tumor models MC signaling synergizes with

  6. Bellicum Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Operational Update

    Raised gross proceeds of $69.6 million from public offering and private placement option fee Narrowed strategic focus to core GoCAR-T® cell therapy programs Cost saving initiatives underway to extend runway to

  7. Bellicum Pharmaceuticals Announces Presentation on CAR-NK Cell Program at SITC 2019

    HOUSTON, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that an abstract for a

  8. Bellicum Pharmaceuticals to Report Third Quarter 2019 Financial Results and Provide Corporate Update

    - Management to host webcast and conference call on Wednesday, November 6, 2019 at 5 p.m. ET / 2 p.m. PT -   HOUSTON, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in

  9. Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    HOUSTON, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today

  10. Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    HOUSTON, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today

  11. Bellicum Pharmaceuticals to Participate in Three Healthcare Investor Conferences during September

    HOUSTON, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today